These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 23750830)

  • 1. Evaluating the in vitro inhibition of UGT1A1, OATP1B1, OATP1B3, MRP2, and BSEP in predicting drug-induced hyperbilirubinemia.
    Chang JH; Plise E; Cheong J; Ho Q; Lin M
    Mol Pharm; 2013 Aug; 10(8):3067-75. PubMed ID: 23750830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro OATP1B1 and OATP1B3 inhibition is associated with observations of benign clinical unconjugated hyperbilirubinemia.
    Chiou WJ; de Morais SM; Kikuchi R; Voorman RL; Li X; Bow DA
    Xenobiotica; 2014 Mar; 44(3):276-82. PubMed ID: 23886114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case study 5. Deconvoluting hyperbilirubinemia: differentiating between hepatotoxicity and reversible inhibition of UGT1A1, MRP2, or OATP1B1 in drug development.
    Templeton I; Eichenbaum G; Sane R; Zhou J
    Methods Mol Biol; 2014; 1113():471-83. PubMed ID: 24523126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Octreotide inhibits the bilirubin carriers organic anion transporting polypeptides 1B1 and 1B3 and the multidrug resistance-associated protein 2.
    Visentin M; Stieger B; Merz M; Kullak-Ublick GA
    J Pharmacol Exp Ther; 2015 Nov; 355(2):145-51. PubMed ID: 26330539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of digitalis-like compounds with liver uptake transporters NTCP, OATP1B1, and OATP1B3.
    Gozalpour E; Greupink R; Wortelboer HM; Bilos A; Schreurs M; Russel FG; Koenderink JB
    Mol Pharm; 2014 Jun; 11(6):1844-55. PubMed ID: 24754247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Hepatobiliary Transport Activity by the Antibacterial Agent Fusidic Acid: Insights into Factors Contributing to Conjugated Hyperbilirubinemia/Cholestasis.
    Lapham K; Novak J; Marroquin LD; Swiss R; Qin S; Strock CJ; Scialis R; Aleo MD; Schroeter T; Eng H; Rodrigues AD; Kalgutkar AS
    Chem Res Toxicol; 2016 Oct; 29(10):1778-1788. PubMed ID: 27676153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans.
    Yamashiro W; Maeda K; Hirouchi M; Adachi Y; Hu Z; Sugiyama Y
    Drug Metab Dispos; 2006 Jul; 34(7):1247-54. PubMed ID: 16624871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The roles of MRP2, MRP3, OATP1B1, and OATP1B3 in conjugated hyperbilirubinemia.
    Keppler D
    Drug Metab Dispos; 2014 Apr; 42(4):561-5. PubMed ID: 24459177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Down-regulation of OATP1B proteins correlates with hyperbilirubinemia in advanced cholestasis.
    Sticova E; Lodererova A; van de Steeg E; Frankova S; Kollar M; Lanska V; Kotalova R; Dedic T; Schinkel AH; Jirsa M
    Int J Clin Exp Pathol; 2015; 8(5):5252-62. PubMed ID: 26191226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation.
    Zhang D; Chando TJ; Everett DW; Patten CJ; Dehal SS; Humphreys WG
    Drug Metab Dispos; 2005 Nov; 33(11):1729-39. PubMed ID: 16118329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms underlying benign and reversible unconjugated hyperbilirubinemia observed with faldaprevir administration in hepatitis C virus patients.
    Sane RS; Steinmann GG; Huang Q; Li Y; Podila L; Mease K; Olson S; Taub ME; Stern JO; Nehmiz G; Böcher WO; Asselah T; Tweedie D
    J Pharmacol Exp Ther; 2014 Nov; 351(2):403-12. PubMed ID: 25204339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-drug interaction between pitavastatin and various drugs via OATP1B1.
    Hirano M; Maeda K; Shitara Y; Sugiyama Y
    Drug Metab Dispos; 2006 Jul; 34(7):1229-36. PubMed ID: 16595711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP) 1B1- and OATP1B3-mediated drug transport.
    Kindla J; Müller F; Mieth M; Fromm MF; König J
    Drug Metab Dispos; 2011 Jun; 39(6):1047-53. PubMed ID: 21389119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia.
    Campbell SD; de Morais SM; Xu JJ
    Chem Biol Interact; 2004 Nov; 150(2):179-87. PubMed ID: 15535988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vectorial transport of enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in rat and human livers.
    Liu L; Cui Y; Chung AY; Shitara Y; Sugiyama Y; Keppler D; Pang KS
    J Pharmacol Exp Ther; 2006 Jul; 318(1):395-402. PubMed ID: 16627748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3.
    Noé J; Portmann R; Brun ME; Funk C
    Drug Metab Dispos; 2007 Aug; 35(8):1308-14. PubMed ID: 17470528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of organic anion-transporting polypeptide 1B1- and 1B3-mediated hepatic uptake of statins based on transporter protein expression and activity data.
    Kunze A; Huwyler J; Camenisch G; Poller B
    Drug Metab Dispos; 2014 Sep; 42(9):1514-21. PubMed ID: 24989890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Further characterization of the electrogenicity and pH sensitivity of the human organic anion-transporting polypeptides OATP1B1 and OATP1B3.
    Martinez-Becerra P; Briz O; Romero MR; Macias RI; Perez MJ; Sancho-Mateo C; Lostao MP; Fernandez-Abalos JM; Marin JJ
    Mol Pharmacol; 2011 Mar; 79(3):596-607. PubMed ID: 21173039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Organic anion transporting polypeptides 1B1 and 1B3 play an important role in uremic toxin handling and drug-uremic toxin interactions in the liver.
    Sato T; Yamaguchi H; Kogawa T; Abe T; Mano N
    J Pharm Pharm Sci; 2014; 17(4):475-84. PubMed ID: 25579430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of hepatic uptake transporters by flavonoids.
    Mandery K; Balk B; Bujok K; Schmidt I; Fromm MF; Glaeser H
    Eur J Pharm Sci; 2012 May; 46(1-2):79-85. PubMed ID: 22394605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.